Company Description

Satellos is dedicated to developing life-improving medicines to treat degenerative muscle diseases and is building a pipeline of novel therapeutics to promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in clinical development as a potential disease-modifying treatment for Duchenne muscular dystrophy.